Hayflick Therapeutics
Company
Hayflick Therapeutics develops one asset, in human trials (topical rapamycin). Mostly programs acting on MTOR.
- 1
- Asset
- Furthest stage
- Human trials
- 0
- Trials
- 0
- Signals
Pipeline
1Localized, micro-dose mTOR suppression reduces markers of cellular aging in skin without systemic exposure.
Human trials, MTOR
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- People8
- Signals1